Your search for oral corticosteroids returned 17 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Post remove
Older than 2 years remove
Drugs in the Pipeline remove

Your search for oral corticosteroids returned 17 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Voclosporin NDA for Lupus Nephritis Submitted to FDA

The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
Drugs in the Pipeline

Oral Tyrosine Kinase Inhibitor Effective in Severe Asthma Trial

Treatment with masitinib, a selective tyrosine kinase inhibitor, significantly reduces the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids, according to data from a phase 3 study.
Drugs in the Pipeline

Baricitinib Added to Topical Steroids Beneficial in Atopic Dermatitis Trial

Adding baricitinib to topical corticosteroids significantly improved disease severity in adult patients with moderate to severe atopic dermatitis, according to top-line results from BREEZE-AD7 study. The phase 3 study included 300 patients who had been diagnosed with moderate to severe atopic dermatitis for at least 12 months and had an inadequate response to topical medications.…
Drugs in the Pipeline

Tezepelumab Gets Breakthrough Therapy Designation for Severe Asthma

The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.
Drugs in the Pipeline

FDA to Review Promacta for First-Line Treatment of Severe Aplastic Anemia

The FDA decision to grant Priority Review was based on results from a National Institute of Health (NIH) study which demonstrated a 52% complete response rate and an 85% overall response rate in treatment-naïve SAA patients treated with eltrombopag plus standard IST.